{
    "id": "dbpedia_2117_3",
    "rank": 37,
    "data": {
        "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/",
        "read_more_link": "",
        "language": "en",
        "title": "Bacterial Pneumonia and Lung Abscess",
        "top_image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "meta_img": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "images": [
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-pheelsevier.png",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/icon02-9781455733835.gif",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-001-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-001-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-002-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-003a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-003b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-003c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-003d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-003e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-004a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-004b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-004c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-004d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-004e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-003ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-005ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-006ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-002-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/icon01-9781455733835.gif",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-007a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-007b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-007c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-007d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-007e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-008ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-004-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-005-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-009ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-010ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-011ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-006-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-007-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-008-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-012a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-012b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-012c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-012d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-012e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-013ac-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-009-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-014ac-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-015-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-016-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-010-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-011a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-011b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-011c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-011d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-011e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-017-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-012ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-018ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-019a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-019b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-019c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-019d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-019e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/f033-013-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-020ad-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-021a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-021b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-021c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-021d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-021e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-022a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-022b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-022c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-022d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-022e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-022f-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-023ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-024ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-025ab-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-026a-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-026b-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-026c-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-026d-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-026e-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-027ac-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-028-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-029ac-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/icon01-9781455733835.gif",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/on033-030ad-9781455733835.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/bin/if033-001-9781455733835.gif"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Antoni Torres",
            "Rosario Menéndez",
            "Richard G. Wunderink"
        ],
        "publish_date": "2016-08-27T00:00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico",
        "meta_site_name": "PubMed Central (PMC)",
        "canonical_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152161/",
        "text": "Murray and Nadel's Textbook of Respiratory Medicine. 2016 : 557–582.e22.\n\nPMCID: PMC7152161\n\nBacterial Pneumonia and Lung Abscess\n\nAntoni Torres, MD, PhD, Rosario Menéndez, MD, PhD, and Richard G. Wunderink, MD, PhD\n\nGuest Editor (s): V. Courtney Broaddus, MD\n\nJohn F. Murray Distinguished Professor of Medicine, University of California San Francisco\n\nChief, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, California\n\nGuest Editor (s): Robert J. Mason, MD\n\nCetalie & Marcel Weiss Chair in Pulmonary Medicine, Department of Medicine, National Jewish Health, Denver, Colorado\n\nProfessor of Medicine, University of Colorado, Denver Health Sciences Center, Aurora, Colorado\n\nGuest Editor (s): Joel D. Ernst, MD\n\nDirector, Division of Infectious Diseases and Immunology, Jeffrey Bergstein Professor of Medicine, Professor of Medicine, Pathology and Microbiology, New York University School of Medicine, NYU Langone Medical Center, New York, New York\n\nGuest Editor (s): Talmadge E. King, Jr., MD\n\nJulius R. Krevans Distinguished Professorship in Internal Medicine, Chair, Department of Medicine, University of California San Francisco, San Francisco, California\n\nGuest Editor (s): Stephen C. Lazarus, MD\n\nProfessor of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Director, Training Program in Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California\n\nAssociate Director, Adult Pulmonary Laboratory, Senior Investigator, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California\n\nGuest Editor (s): John F. Murray, MD, FRCP, DSc (Hon)\n\nProfessor Emeritus, Department of Medicine, University of California San Francisco, San Francisco General Hospital, San Francisco, California\n\nGuest Editor (s): Jay A. Nadel, MD, DSc (Hon), DLaw (Hon)\n\nProfessor of Medicine, Physiology, and Radiology, Division of Pulmonary and Critical Care Medicine, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California\n\nGuest Editor (s): Arthur S. Slutsky, MD\n\nKeenan Chair in Medicine, Professor of Medicine, Surgery and Biomedical Engineering, University of Toronto\n\nVice President (Research), St. Michael's Hospital, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada\n\nGuest Editor (s): Michael B. Gotway, MD\n\nProfessor of Radiology, Mayo Clinic, Scottsdale, Arizona\n\nClinical Associate Professor, Diagnostic Radiology/Biomedical Imaging and Pulmonary/Critical Care Medicine, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California\n\nClinical Professor, University of Arizona College of Medicine, Phoenix, Arizona\n\nAdjunct Professor, Department of Biomedical Informatics, Arizona State University, Tempe, Arizona\n\nCopyright © 2016 Elsevier Inc. All rights reserved.\n\nSince January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.\n\nAn expanded version of this chapter is available online at ExpertConsult.\n\nIntroduction\n\nCommunity-acquired pneumonia (CAP) is a frequent infectious respiratory disease.1 Although many patients with CAP can be treated as outpatients, the mortality of CAP in those who do require hospitalization ranges from 5% to 15% and increases to 20% to 50% in patients who require intensive care unit (ICU) care. Hospital-acquired pneumonia (HAP) is the second most common and most frequently fatal nosocomial infection.\n\nA clinical diagnosis of pneumonia can usually be established on the basis of signs, symptoms, and chest radiographs, although distinguishing CAP or HAP from conditions such as congestive heart failure, pulmonary embolism, and chemical aspiration pneumonia is sometimes difficult. Defining an etiologic agent is also challenging. Although early empirical therapy is necessary, it is important to identify the causative pathogen in patients who require hospitalization, both to confirm the appropriateness of therapy and to reduce unnecessary antimicrobial use.\n\nDiagnosis and management of pneumonia has become more complex due to the growing number of aged and comorbid, debilitated, institutionalized, and immunocompromised individuals, to the diverse array of microorganisms that cause pneumonia, and to increasing antimicrobial resistance.\n\nPathophysiology and Pathogenesis\n\nAspiration of oropharyngeal or nasopharyngeal secretions is the main mechanism of contamination of lower airways by bacteria. While a person is awake, glottal reflexes prevent aspiration; during sleep, 50% of normal persons aspirate small volumes of pharyngeal secretions. Because oropharyngeal secretions may contain 107 to 1011 microorganisms per milliliter, aspiration of as little as 0.001 mL may carry more than 100,000 bacteria.\n\nThe oropharynx of healthy individuals is colonized by diverse microorganisms that vary in their potential virulence. The ability of microorganisms to colonize the oropharynx and to cause lower respiratory tract infections is determined in part by the interaction of specific microbial adhesins with cellular receptors. For example, Streptococcus pneumoniae, which contains multiple adhesions,2 binds to the receptor for platelet-activating factor on epithelial cells, and this interaction is enhanced by cigarette smoke, infection with respiratory viruses, and particulate air pollutants,3, 4, 5 all of which are linked to increased risk for pneumococcal pneumonia. Likewise, Staphylococcus aureus expresses multiple adhesins that bind host extracellular matrix proteins.6, 7 Gram-negative bacterial pathogens also possess specific adhesins, many of which form macromolecular structures, termed pili. Klebsiella pneumoniae exploits two distinct pili to adhere to epithelial cells: type 1 pili bind to diverse host target molecules with exposed mannose residues, and type 3 pili interact with extracellular matrix proteins.8\n\nSeveral mechanisms in the airways prevent adherence and colonization by potential bacterial pathogens. Respiratory epithelial cells synthesize and secrete peptides, termed defensins and cathelicidins, that possess broad-spectrum antimicrobial activity.9 In the distal airways and alveoli, pulmonary surfactant proteins A and C can inhibit bacterial binding to host cells and also promote phagocytosis of selected bacteria.10, 11 The presence of complement and immunoglobulins (particularly immunoglobulin A [IgA]), also prevents colonization of the oropharynx. In addition to protection provided by host factors, the upper airway microbiota may modulate susceptibility to pathogens, as indicated by the evidence that broad-spectrum antimicrobial therapy predisposes to colonization and infection. The effects of the microbiota operate through competition for binding sites or nutritional resources, or by modulating expression of specific host defense molecules.12, 13, 14, 15 Interactions between the virulence and quantity of aspirated or inhaled microorganisms and the individual's innate and adaptive immune responses determine whether pneumonia develops.16\n\nAs an alternative to aspiration of bacteria of the upper airways, Mycoplasma pneumoniae, Chlamydophila species, Coxiella burnetii, Legionella, and Mycobacterium tuberculosis enter the lower respiratory tract by inhalation. Inhalation pneumonia is most often due to microorganisms that survive suspended in the air for prolonged periods, are present in droplet nuclei smaller than 5 µm, and are able to evade innate immune responses.\n\nEpidemiology\n\nCommunity-Acquired Pneumonia\n\nThe true incidence of CAP is uncertain because the illness is not reportable and only 20% to 50% of patients require hospitalization. Estimates of the incidence of CAP range from 2 to 15 cases per 1000 persons per year, with substantially higher rates in older adults.17\n\nAlthough the severity of disease is influenced by the patient's age and by the presence and type of coexisting conditions,18, 19, 20, 21 the severity of disease is also related to the pathogen. M. pneumoniae, S. pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, and viruses are causes of mild CAP ( ), whereas S. pneumoniae, M. pneumoniae, and H. influenzae can cause CAP severe enough to warrant hospitalization ( ).21, 22, 23 The most frequently identified pathogens causing severe CAP (i.e., CAP requiring ICU care) include S. pneumoniae, enteric gram-negative bacilli, S. aureus, Legionella pneumophila, M. pneumoniae, H. influenzae, and respiratory viruses ( ).21, 22, 23, 24, 25 Up to 20% of severe CAP episodes are caused by polymicrobial infection. Even if extensive diagnostic procedures are performed, the responsible pathogen is not isolated in up to 50% to 60% of patients with severe CAP.\n\nTable 33-1\n\nMycoplasma pneumoniae\n\nStreptococcus pneumoniae\n\nChlamydophila pneumoniae\n\nHaemophilus influenzae\n\nRespiratory viruses\n\nTable 33-2\n\nStreptococcus pneumoniae\n\nMycoplasma pneumoniae\n\nChlamydophila pneumoniae\n\nHaemophilus influenzae\n\nStaphylococcus aureus\n\nMixed infections\n\nEnteric gram-negative bacilli\n\nAspiration (anaerobes)\n\nRespiratory viruses\n\nLegionella species\n\nTable 33-3\n\nStreptococcus pneumoniae\n\nEnteric gram-negative bacilli\n\nStaphylococcus aureus\n\nLegionella species\n\nMycoplasma pneumoniae\n\nRespiratory viruses\n\nPseudomonas aeruginosa (relative frequency determined by the presence or absence of specific risk factors)\n\nGram-negative enteric bacilli, S. aureus, Legionella species, and respiratory viruses are uncommon causes of CAP, although local outbreaks can markedly increase the incidence of Legionella.26, 27 Methicillin-resistant Staphylococcus aureus (MRSA), originally a nosocomial pathogen, has appeared in the community where it is referred to as community-acquired MRSA. Community-acquired MRSA can lead to severe pulmonary infections, including necrotizing and hemorrhagic pneumonia.28 Pseudomonas aeruginosa infection is uncommon in the absence of specific risk factors (recent antibiotic treatment, acquired immunodeficiency syndrome [AIDS], and severe pulmonary comorbidity, especially bronchiectasis, cystic fibrosis, and severe chronic obstructive pulmonary disease [COPD]).21, 22, 24\n\nThe likely etiology of severe CAP varies in differing patient populations, depending on age and comorbidities, including HIV infection.22, 29, 30, 31, 31a\n\nAge-Related Factors\n\nPneumonia remains one of the major causes of morbidity in children. In Europe, there are more than 2.5 million cases of childhood pneumonia yearly, which account for about 50% of hospital admissions for children. Radiographically defined pneumonia is present in 7.5% of febrile illnesses in infants up to 3 months old and in 13% of infectious illnesses during the first 2 years of life. In children younger than 2 years, S. pneumoniae and respiratory syncytial virus are the most frequent microorganisms, whereas M. pneumoniae is a leading cause of pneumonia in older children and young adults.\n\nIn adults, increased age is associated with a change in the distribution of microbial causes and an increase in the frequency and severity of pneumonia.32 The annual incidence of CAP in noninstitutionalized older adults is estimated between 18 and 44 per 1000 compared with 4.7 to 11.6 per 1000 in the general population.17, 32, 33 Although older adults are particularly at risk for pneumococcal pneumonia, they also have increased rates of pneumonia due to group B streptococci, Moraxella catarrhalis, H. influenzae, L. pneumophila, gram-negative bacilli, C. pneumoniae, and polymicrobial infections.17, 24, 34 Although the absolute rate of infection by M. pneumoniae does not decrease with age, this pathogen accounts for a smaller proportion of pneumonia in older adults than in younger populations. In patients older than 80 years, there is a higher incidence of aspiration pneumonia and lower incidence of infection with Legionella species than in younger patients.35\n\nPersonal Habits\n\nAlcohol consumption is an important risk factor for CAP because of its potential to impair level of consciousness, thus increasing the risk for aspiration of oropharyngeal contents. In addition, diverse effects of alcoholism on innate and adaptive immunity have been reported, which may contribute to increased risk. Alcoholism has been shown to be an independent risk factor for increased rate and severity of pneumonia, especially that due to S. pneumoniae. 36, 37 This predisposition persists several months after cessation of alcohol consumption.37\n\nSmoking is one of the most important risk factors for CAP and is associated with an increased frequency of CAP due to S. pneumoniae, L. pneumophila, and influenza.38 Smoking alters mucociliary transport and humoral and cellular defenses, affects epithelial cells, and increases adhesion of S. pneumoniae and H. influenzae to the oropharyngeal epithelium.4\n\nComorbidities\n\nThe most frequent comorbidity associated with CAP is COPD. Patients with COPD have an increased risk for CAP, due to alterations in mechanical and cellular defenses that allow bacterial colonization of the lower airways. Patients with severe COPD (forced expiratory volume in 1 second < 30% of predicted) and bronchiectasis have an increased risk for pneumonia caused by H. influenzae and P. aeruginosa. 38 In patients with COPD treated with oral corticosteroids for long periods, the risk for infection with Aspergillus species is increased.39\n\nPneumonia remains the major cause of morbidity and mortality in patients with cystic fibrosis. During the first decade of life, S. aureus and nontypeable H. influenzae are the most common pathogens, although P. aeruginosa is occasionally isolated in infants. By 18 years of age, 80% of patients with cystic fibrosis harbor P. aeruginosa and 3.5% harbor Burkholderia cepacia. 40 Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria are emerging pathogens in this population.41\n\nOther comorbidities associated with increased rates of CAP and consequent mortality include congestive heart failure, chronic kidney or liver disease, cancer, diabetes, dementia, cerebrovascular diseases, and immunodeficiencies (e.g., neutropenia, lymphoproliferative diseases, immunoglobulin deficiencies, and human immunodeficiency virus [HIV] infection).42, 43, 44\n\nGeographic and Occupational Considerations\n\nGeographic factors, seasonal timing, travel history, and occupational or unusual exposures modify the risk of various microbial etiologies of CAP. For example, an increased frequency of S. pneumoniae is found in soldiers, painters, and South African gold miners. Burkholderia pseudomallei (melioidosis) is endemic in the rural tropics.45 Exposure to pet birds or work on a poultry (especially turkey) farm or processing plant increases the risk of psittacosis (Chlamydophila psittaci), while contact with horses or other large mammals including cattle, swine, sheep, goats, or deer increases exposure to Rhodococcus. Rodent contact suggests the possibility of infection with Yersinia pestis (plague) in the rural southwestern United States46 and Francisella tularensis (tularemia) in rural Arkansas or Nantucket, Massachusetts.47 Exposure to sheep, dogs, and cats should prompt evaluation for Coxiella burnetii (Q fever).48 The role of seasonal timing is illustrated by the increased incidence of lower respiratory tract infections due to S. pneumoniae and H. influenzae in winter months. Pneumonia causing the severe acute respiratory syndrome (SARS) due to a coronavirus emerged in epidemic form in Southeast Asia,49, 50 and another coronavirus causes the emerging Middle East respiratory syndrome (MERS). Finally, the infectious agents that cause anthrax, tularemia, and plague may be used for bioterrorism or biowarfare purposes and cause lower respiratory tract infections.51, 52\n\nHospital-Acquired (Nosocomial) Pneumonia\n\nEarly-onset HAP (<5 days of hospitalization) is most often due to microorganisms that are also associated with CAP, such as S. pneumoniae, H. influenzae, and anaerobes. Late-onset HAP (>5 days of hospitalization) is mainly caused by MRSA, enteric gram-negative bacilli, P. aeruginosa, nonfermenters such as Acinetobacter baumannii and S. maltophilia, and polymicrobial infections.53 Factors that increase the risk for HAP include antibiotic exposure, old age, severe comorbidities, underlying immunosuppression, colonization of the oropharynx by virulent microorganisms, conditions that promote pulmonary aspiration or inhibit coughing (e.g., thoracoabdominal surgery, endotracheal intubation, insertion of nasogastric tube, supine position), and exposure to contaminated respiratory equipment. A recent study suggests that multidrug-resistant microorganisms are more frequent in early-onset HAP than was initially thought54 and that risk factors for early-onset pneumonia should be reappraised.\n\nHealth Care–Associated Pneumonia\n\nHealth care now reflects a continuum with many traditional inpatient services provided in outpatient settings. Physicians often categorize new infections in such subjects as “community-acquired.” However, these health care–associated infections have a unique epidemiology more like that of hospital-acquired infections, and this has resulted in health care–acquired pneumonia (HCAP) being recognized as a separate entity by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA).53 S. aureus (both methicillin-sensitive and methicillin-resistant) and P. aeruginosa are the most frequent associated microorganisms. Compared with CAP, HCAP patients have more severe disease, higher mortality, greater length of hospital stay, and greater cost of care.55\n\nClinical Presentation\n\nPneumonia is characterized by the presence of fever, altered general well-being, and respiratory symptoms, such as cough (90%), sputum production (66%), dyspnea (66%), pleuritic pain (50%), and hemoptysis (15%). In older and immunocompromised patients, the signs and symptoms of pulmonary infection may be muted and overshadowed by nonspecific complaints. Temperature greater than 38.5° C or accompanied by chills should never be attributed to bronchitis without examining a chest radiograph.\n\nOccasionally, there is a “classic” history, such as that of the patient with pneumococcal infection who presents with sudden onset of rigor followed by pleuritic chest pain, dyspnea, and cough with rusty sputum. Similarly, a patient with Legionella pneumonia may complain pre­dominantly of diarrhea, fever, headache, confusion, and myalgia. For M. pneumoniae infection, extrapulmonary manifestations such as myringitis, encephalitis, uveitis, iritis, and myocarditis may be present. However, only rarely does the clinical history clearly suggest a specific etiologic diagnosis.\n\nInformation obtained from the clinical history and physical examination is not sufficient to confirm the diagnosis of pneumonia. A definitive diagnosis requires the finding of a new opacity on the chest radiograph.\n\nIn older patients, especially those with multiple comorbidities, pneumonia may present with general weakness, decreased appetite, altered mental status, incontinence, or decompensation due to underlying disease. The presence of tachypnea may precede other signs of pneumonia by 1 to 2 days. Tachycardia is another common initial sign but is less frequent and specific than tachypnea. Fever is absent in 30% to 40% of older patients. Owing to the lack of specific symptoms, the diagnosis of CAP is frequently delayed in older adults.17, 34 Older patients with pneumonia who present with altered mental status without fever can have a delay in receiving antibiotics by more than 4 hours after arrival; this delay increases mortality.56\n\nTypical Versus Atypical Pneumonia\n\nThe division of CAP into typical and atypical syndromes has been used to predict the likely pathogens and select appropriate empirical therapy.18, 19, 20, 21 The clinical picture of “typical” CAP is that of disease characteristically caused by bacteria such as S. pneumoniae, H. influenzae, and K. pneumoniae. The initial presentation is frequently acute, with an intense chill. Productive cough is present, and the sputum is purulent or bloody. Pleuritic pain may suggest S. pneumoniae. Physical examination reveals typical findings of pulmonary consolidation (see Chapter 16). Blood tests show leukocytosis with neutrophilia and the presence of band forms in most cases. Chest radiography shows lobar consolidation with air bronchograms ( ).\n\nIn contrast, the syndrome of gradual onset of fever, nonproductive cough, and a relatively normal white blood cell count in a patient without a readily demonstrable bacterial pathogen has been called “atypical pneumonia.” Frequently, systemic complaints are more prominent than the respiratory ones. The atypical syndrome is characteristic of infections by pathogens such as M. pneumoniae, Chlamydophila species, C. burnetii, and viruses. However, several studies, including one that included patients with mild CAP treated on an outpatient basis,57 have found that neither the clinical symptoms nor the radiographic manifestations are sufficiently sensitive or specific to guide pathogen-directed antibiotic treatment against “typical” versus “atypical” microorganisms.57 Therefore, current guidelines do not emphasize the use of the typical versus atypical classification to determine initial empirical antibiotic treatment for CAP.18, 19, 20, 21, 58\n\nPatient Evaluation\n\nClinical Evaluation\n\nThe clinical findings that best differentiate CAP from other acute respiratory tract infections are cough, fever, tachypnea, tachycardia, and pulmonary crackles; CAP is present in 20% to 50% of persons who have all five factors.59 Specific signs of pulmonary consolidation are present in only one third of the cases that warrant hospitalization and are frequently absent in patients that are less ill. Early in the evolution of disease, pain and cough may be absent and the physical examination may be normal other than for fever. In debilitated older patients, vague clinical manifestations of pneumonia are common and the presence of fever with no apparent source, especially when accompanied by confusion or tachypnea, justifies obtaining a chest radiograph.\n\nClues to the etiologic diagnosis may lie outside the respiratory tract. Bradycardia in relation to the amount of fever (pulse should increase by 10 beats/min/°C of temperature elevation) has been associated with pneumonia due to Legionella, C. psittaci, Mycoplasma, or F. tularensis. M. pneumoniae infection may present with extrapulmonary manifestations including arthralgia, cervical lymphadenopathy, bullous myringitis, diarrhea, myalgia, myocarditis, hepatitis, nausea, pericarditis, and vomiting.60 Skin lesions of erythema multiforme or erythema nodosum suggest Mycoplasma infection (as well as tuberculosis and endemic fungal infection), whereas lesions of ecthyma gangrenosum are most often seen with P. aeruginosa infection. Finally, the examiner must look for the presence of complications such as pleural effusion, pericarditis, endocarditis, arthritis, and central nervous system involvement, which may necessitate further diagnostic procedures and, potentially, a change in therapy.61\n\nLaboratory Evaluation\n\nOnce the patient is suspected to have pneumonia, laboratory studies should include blood cell counts, serum glucose and electrolyte measurements, and pulse oximetry or arterial blood gas assays.18, 19, 20, 21 These data provide a basis for making decisions regarding the need for hospitalization. The increased incidence of CAP in HIV-infected individuals provides an additional rationale for HIV testing, particularly in patients with no other risk factors for CAP.\n\nMarked leukocytosis with a leftward shift is more often encountered with infections caused by S. pneumoniae, H. influenzae, and gram-negative bacilli than with M. pneumoniae, Chlamydophila species, Coxiella, or nonbacterial causes of pneumonia. Leukopenia may be seen with overwhelming pneumococcal or gram-negative bacillary pneumonia. The serum level of C-reactive protein and the erythrocyte sedimentation rate are increased to higher values with bacterial than with viral pneumonias. Thrombocytopenia and thrombocytosis are associated with a greater severity of pneumonia and higher mortality.\n\nProcalcitonin (PCT), a precursor of calcitonin, is present at increased concentrations in the blood of persons with bacterial infections, and PCT assays have been used to evaluate the severity, prognosis, and evolution of pneumonia.62 Importantly, procalcitonin is used to deescalate antibiotics or to stop antibiotics when the levels decrease to a certain cutoff point.63 A randomized trial of a PCT-guided strategy compared with a guideline-based algorithm, revealed equivalent primary outcomes of treatment of lower respiratory tract infections, but the PCT-guided strategy resulted in reduced antibiotic exposure and duration, fewer adverse effects of antibiotic treatment, and shorter length of stay.64\n\nRadiographic Evaluation\n\nRadiographic evaluation is necessary to establish the presence of pneumonia, because there is no combination of historical data, physical findings, or laboratory results that reliably confirms the diagnosis.18, 21, 59, 65 Limitations of chest radiography include interobserver variability and suboptimal specificity, particularly in patients with the acute respiratory distress syndrome (ARDS).21 Conversely, the sensitivity of the chest radiograph is decreased in (1) patients with emphysema, bullae, or structural abnormalities of the lung, who may present with delayed or subtle radiographic changes; (2) obese patients, in whom it may be difficult to discern the existence of pneumonia; and (3) patients with very early infection, severe dehydration, or profound granulocytopenia. Computed tomography (CT) of the chest provides a more sensitive means of detecting minor radiographic abnormalities.59 However, a chest CT is not recommended for patients with suspected pneumonia who have an apparently normal chest radiograph.21\n\nAlthough several radiographic patterns have been associated with pneumonia caused by specific microorganisms, the presence of a certain pattern is not a reliable method for diagnosing a specific pathogen.66, 67 Nonetheless, the presence of air bronchograms and a lobar ( ) or segmental pattern is more characteristic of typical than atypical causes of pneumonia. In contrast, a mixed pattern (alveolar and interstitial disease ( ) is more frequently observed with atypical pneumonias. Pneumonia complicating aspiration (frequently from anaerobes) ( ) most often involves the superior segment of the right lower lobe or posterior segment of the right upper lobe, or both, as well as the corresponding segments on the left. Infections developing from hematogenous seeding often appear as multiple rounded, small opacities, sometimes with cavities, with a basal predominance, where the distribution of blood flow is greatest. Demonstration of a lung abscess ( ), cavitation, or necrotizing pneumonia suggests infection by anaerobes, S. aureus, Streptococcus pyogenes, or gram-negative bacilli. Pleural effusion frequently accompanies pneumonia; the size of the pleural effusion on the chest radiograph helps determine whether thoracentesis should be performed.\n\nMicrobiologic Evaluation\n\nIdentification of the infecting microorganism facilitates the use of specific therapy instead of unnecessarily broad-spectrum antimicrobial agents. Although the utility of sputum examination is debated (see later), pleural fluid (if present) and two sets of blood cultures should be obtained in patients hospitalized for CAP. Optimal culture results require that specimens be obtained before initiation of antimicrobial therapy. Sputum samples must be carefully collected, transported, and processed in order to optimize the recovery of common bacterial pathogens. These recommendations are summarized in and .\n\nTable 33-4\n\nPATIENTS WHO DO NOT REQUIRE HOSPITALIZATIONNone*PATIENTS WHO REQUIRE HOSPITALIZATION\n\nTwo sets of blood cultures (obtained prior to antibiotics)\n\nGram stain and culture of a valid sputum sample\n\nUrinary antigen test for detection of Legionella pneumophila (in endemic areas or during outbreaks)\n\nStain for acid-fast bacilli and culture of sputum (if tuberculosis is suggested by clinical history or radiologic findings)\n\nFungal stain and culture of sputum, and fungal serologies (if infection by an endemic mycosis is suggested by the clinical history or radiologic findings)\n\nSputum examination for Pneumocystis jirovecii (if suggested by clinical history or radiologic findings)\n\nNucleic acid amplification tests for Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, Coxiella burnetii, Legionella species, and respiratory viruses (in endemic areas or during outbreaks)\n\nCulture and microscopic evaluation of pleural fluid (if significant fluid is present)\n\nADDITIONAL TESTS FOR PATIENTS WHO REQUIRE TREATMENT IN AN ICU\n\nGram stain and culture of endotracheal aspirate or bronchoscopically obtained specimens using a protected specimen brush or BAL\n\nOther procedures as for other hospitalized patients\n\nTable 33-5\n\nTwo sets of blood cultures\n\nGram stain and culture of a valid sputum sample*\n\nUrinary antigen test for detection of Legionella pneumophila (in endemic areas or during outbreaks)\n\nSputum Examination\n\nMicroscopic examination of expectorated sputum is the easiest and most rapidly available method of evaluating the microbiology of lower respiratory tract infections. A valid expectorated sputum specimen can be obtained in about 40% of patients hospitalized with CAP. When interpreting sputum cultures, it is crucial to ensure that oropharyngeal contents do not unduly contaminate the specimens. The presence of more than 10 squamous epithelial cells per low-power field (×100 magnification) indicates excessive oropharyngeal contamination and the specimen should be discarded because it is not representative of the pulmonary milieu.18 A specimen with few or no squamous cells and many polymorphonuclear white blood cells (>25 cells/low-power field in a sample from a patient who is not granulocytopenic68) is ideal (see ). Gram-stained expectorated sputum specimens of acceptable quality should be carefully examined using ×1000 magnification (oil immersion objective). Specific fluorescent antibodies are used to evaluate sputum or other respiratory tract specimens for the presence of Legionella and selected other pathogens (see Chapter 17).\n\nWhen acceptable sputum is obtained, the specificity of the Gram stain for pneumococcal pneumonia is estimated to be greater than 80%.69 Because the fastidious nature of S. pneumoniae and H. influenzae leads to the death of these organisms, the sensitivity of sputum culture may be lower than that of sputum Gram stain examination for S. pneumoniae or H. influenzae. In contrast, S. aureus and gram-negative bacilli may dominate even if they are not the cause of the patient's illness, because these bacteria are hardier and may proliferate during sample transport and processing. True pneumonia due to S. aureus or gram-negative bacilli is doubtful if the Gram stain of a valid sputum specimen does not corroborate the presence of these bacteria. In good quality Gram-stained sputum, the presence of a single or a preponderant morphotype of bacteria (≥90%) is considered diagnostic. In the absence of an informative Gram stain, the predictive value of sputum culture is very low.\n\nThe latest IDSA/ATS guidelines58 recommend obtaining a sputum sample for Gram stain and culture in hospitalized patients with the clinical indications listed in but are optional for patients without these conditions.\n\nTable 33-6\n\nIntensive care unit admission\n\nFailure of outpatient antibiotic therapy\n\nRadiographic cavities\n\nLeukopenia\n\nActive alcohol abuse\n\nChronic severe liver disease\n\nSevere obstructive/structural lung disease\n\nAsplenia\n\nRecent travel (within past 2 weeks)\n\nPositive Legionella UAT result\n\nPositive pneumococcal UAT result\n\nPleural effusion\n\nFrom Mandell LA, Wunderink RG, Anzueto A: Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia. Clin Infect Dis 44(Suppl 2):S27–S72, 2007.\n\nFor patients with HAP or ventilator-associated pneumonia (VAP), the range of potential pathogens is so broad and antimicrobial susceptibility patterns so diverse that vigorous diagnostic measures are justified. In ventilated patients, the equivalent of sputum is the endotracheal aspirate for which the criteria for validity are the same as those for sputum. Although the Gram stain and qualitative cultures of endotracheal aspirates have excellent sensitivity, they have poor specificity.70 Quantitative cultures of endotracheal aspirate samples may help distinguish colonization from infection. However, there has been difficulty in choosing a quantitative threshold for VAP; some have chosen to consider a range of quantitative cultures, from 103 to 106 CFU/mL, rather than a single cutoff.71\n\nSome bacterial agents of pneumonia cannot be cultivated on conventional laboratory media. For example, Legionella requires buffered charcoal yeast extract agar for isolation, whereas recovery of Chlamydophila species and C. burnetii requires culture in mammalian cell lines. When necessary, specimens can be sent to specialized or reference laboratories for appropriate procedures. Culture of certain agents of bacterial pneumonia poses major health risks to laboratory workers (e.g., F. tularensis, Bacillus anthracis, C. burnetii). Specimens suspected to harbor one of these agents should be dealt with carefully in a biologic safety hood, and isolation of the pathogens should be reserved for specialized laboratories.\n\nBlood and Pleural Fluid Cultures\n\nAlthough the overall yield of blood cultures is less than 20% in patients hospitalized for CAP, a positive culture of blood or pleural fluid establishes the etiologic diagnosis of pneumonia.72, 73 Not surprisingly, the detected rate of bacteremia is lower in patients with mild CAP and higher in patients with severe CAP, especially those warranting ICU care. Prior antibiotic treatment decreases the yield of blood cultures.74 The latest IDSA/ATS guidelines58 recommend obtaining blood samples for culture in hospitalized patients with the clinical indications listed in but are optional for patients without these conditions.\n\nIn up to 40% of CAP cases, a pleural effusion may be present. Although the specificity of pleural exudate cultures is very high, the sensitivity is low because of the low incidence of invasion of the pleura. Diagnostic thoracentesis should be performed when a significant pleural effusion is present. Gram stain of pleural fluid may produce an indication of the infecting organisms within 1 hour, while culture identification may require 24 to 48 hours.\n\nAntigen Detection\n\nCommercial assays can be used to detect capsular polysaccharide antigens of S. pneumoniae or L. pneumophila serogroup 1 in urine, and can require less than 1 hour.69, 74, 75 The sensitivity of these tests is little affected by prior antibiotic treatment; indeed, results may remain positive several weeks after successful treatment. For L. pneumophila serogroup 1, the sensitivity is 60% to 80%, and the specificity is greater than 95%.76 Urinary antigen testing is currently the most helpful rapid test for the diagnosis of Legionella infections. The major limitation of urinary antigen tests is that currently available tests are intended to detect L. pneumophila serogroup 1 antigen only, although this is the most common cause of Legionella infection.\n\nThe sensitivity of S. pneumoniae urinary antigen detection is 50% to 80% and the specificity is 90%.77 The degree of positivity for the S. pneumoniae urinary antigen test correlates with the Pneumonia Severity Index (PSI).78 The S. pneumoniae antigen test may also be applied on pleural fluid with a sensitivity and specificity of almost 100%. Urine specimens of children, frequent carriers of S. pneumoniae in the nasopharynx, may test positive in the absence of evidence of pneumonia, and the test should therefore be interpreted with caution in children.79 The most recent IDSA/ATS guidelines58 recommend S. pneumoniae and L. pneumophila urinary antigen detection in hospitalized patients with the clinical indications listed in , but are optional for patients without these conditions.\n\nAntigens for the many common respiratory viruses, influenza virus, respiratory syncytial virus, adenovirus, and parainfluenza viruses can be detected by direct immunofluorescence or by enzyme-linked immunoassay. A rapid antigen detection test for influenza can provide an etiologic diagnosis within 15 to 30 minutes. Test performance varies according to the test used, viral strain, sample type, duration of illness, and patient age. Most show a sensitivity ranging from 50% to 70% and a specificity approaching 100% in adults (see Chapter 17).\n\nNucleic Acid Amplification Tests\n\nCulture procedures for viruses and fastidious bacteria, M. pneumoniae, C. pneumoniae, L. pneumophila, and Bordetella pertussis, which normally do not colonize in the human respiratory tract, are too insensitive and too slow to be helpful in guiding therapy. These pathogens should be detected by nucleic acid amplification tests; their sensitivity is generally superior to that of the traditional procedures and some are considered as the “gold standard.”80 Real-time multiplex polymerase chain reaction assays detect respiratory viruses in both immunocompetent and immunosuppressed hosts.81 (See Chapter 17 for detailed information on nucleic acid amplification tests for respiratory pathogens.)\n\nSerologic Evaluation\n\nBefore the development of nucleic acid amplification tests, serologic techniques were used to establish a microbiologic diagnosis for pneumonia caused by pathogens that cannot be readily cultured. Examples include common pathogens such as M. pneumoniae, C. pneumoniae, and L. pneumophila, and less common causes of pneumonia such as those caused by the agents of tularemia, brucellosis, and psittacosis, and certain viruses. Diagnosis usually requires that a convalescent specimen demonstrate a fourfold increase in immunoglobulin (Ig) G titer above that present in an acute specimen. These tests are not helpful in initial patient management but are of utility in defining the epidemiology of the pertinent infectious agents. Because IgM antibodies appear earlier than IgG antibodies, the detection of pathogen-specific IgM in serum has been used for the early serologic diagnosis of certain acute infections.\n\nInvasive Diagnostic Techniques\n\nBecause of problems encountered with the use of expectorated sputum, it may be necessary to perform an invasive procedure to obtain suitable material for microscopy and cultures. This may be important in the management of patients with life-threatening CAP in whom diagnostic materials cannot otherwise be obtained, patients with progressive pneumonia despite seemingly appropriate antimicrobial therapy, immunocompromised patients, and patients with HAP, especially in the setting of endotracheal intubation.61, 82 Although qualitative culture of materials obtained by endotracheal suction has excellent sensitivity, the specificity of such cultures is poor; thus, overreliance on these cultures can lead to antibiotic overtreatment.71\n\nBronchoscopic Samples\n\nThe reliability of bronchoscopic procedures to determine the microbial etiology of pneumonia depends on the technique used and the organism sought. When compared with sputum cultures, optimally processed bronchoscopic specimens demonstrate improved sensitivity and equal specificity for the culture of pathogenic fungi and mycobacteria. However, such materials have unacceptably poor specificity for routine bacterial cultures owing to oropharyngeal contamination. Semiquantitative or quantitative cultures of materials obtained bronchoscopically with a protected sheath brush or through bronchoalveolar lavage (BAL) and by direct lung aspiration have been successfully used for aerobic and anaerobic bacterial cultures83, 84, 85 (see Chapters 17 and 22). For protected sheath brush cultures, a threshold of 103 colony-forming units (CFU)/mL has been recommended to distinguish colonization from infection. However, 14% to 40% of duplicate samples yield disparate quantitative results.\n\nBAL fluid can be quantitatively cultured for bacteria and qualitatively cultured for fungi, mycobacteria, and viruses. A concentrate can be stained for cytochemical and fluorescence evaluation.85 In one study, the threshold of 103 CFU/mL for diagnosing bacterial pneumonia correlated well with diagnoses based on protected sheath brush results and histologic examination of the lung.86 BAL permits identification of contaminated specimens (i.e., those with greater than 1% squamous epithelial cells), the immediate diagnosis of infection (i.e., intracellular bacteria in more than 2% to 5% of examined polymorphonuclear leukocytes), and the exclusion of infection (i.e., the absence of bacterial pathogens in culture of BAL fluid, although the sensitivity is reduced by prior antibiotic administration).87, 88\n\nIn one study, the use of quantitative cultures obtained by protected sheath brush and BAL, compared with qualitative cultures of endotracheal aspirates and clinical evaluation, was associated with lower 14-day mortality rates, earlier reversal of organ dysfunction, and less antibiotic use.89 However, other randomized trials on the use of quantitative cultures of protected sheath brush and BAL specimens, rather than quantitative cultures of endotracheal aspirates, in patients with VAP have not replicated these findings.90, 91 The use of a sophisticated algorithm (i.e., Clinical Pulmonary Infection Score) increases the diagnostic accuracy of clinical judgment.92\n\nTransthoracic Lung Aspiration\n\nTransthoracic lung aspiration obtains specimens suitable for microbiologic and cytologic examination directly from lung parenchyma ( ). It is more widely used for diagnosing malignant pulmonary lesions than infectious diseases, for which, in immunocompetent hosts, the diagnostic yield by transthoracic lung aspiration is approximately 50%. Serious complications of transthoracic lung aspiration include pneumothorax and hemoptysis, even when small-gauge needles are used.\n\nDifferential Diagnosis\n\nSeveral diseases may present with fever and chest radiographic opacities and mimic CAP ( )59; such diseases should be suspected when the radiographic resolution is unusually quick or when there is a lack of response to initial or subsequent antibiotic treatments. In patients with HAP, and particularly in those with VAP, the classic signs and symptoms of pneumonia (including new radiographic changes, fever, leukocytosis or leukopenia, and purulent pulmonary secretions) are neither sufficiently sensitive nor specific to confirm the presence of a pulmonary infection. Atelectasis, pulmonary hemorrhage, ARDS, and pulmonary embolism, among others, are conditions that may mimic pneumonia. In patients with suspected HAP or VAP, the microbiologic confirmation of pneumonia is important in order to avoid unnecessary treatments and increased antibiotic resistance.\n\neTable 33-1\n\nPulmonary edemaPulmonary infarctionAcute respiratory distress syndromePulmonary hemorrhageLung cancer or metastatic cancerAtelectasisRadiation pneumonitisDrug reactions involving the lungExtrinsic allergic alveolitisPulmonary vasculitisPulmonary eosinophiliaOrganizing pneumonia\n\nTherapeutic Approach to Pneumonia\n\nOnce the diagnosis of pneumonia is made, the clinician must decide the appropriate treatment setting: outpatient, general hospital bed, or ICU. Applying prediction rules can facilitate this decision. The second key initial decision is the selection of initial antimicrobial therapy.\n\nAssessment of Severity\n\nThe PSI ( ) is a scoring system derived from a retrospective analysis of a cohort of 14,199 patients with CAP and prospectively validated in a separate cohort of 38,039 patients with CAP.93 The PSI is heavily weighted by age, which means it is less useful at extremes of age and is not valid in children. Outpatient treatment is recommended for patients with a PSI score of 70 or less (class I or II). Patients with a PSI score of 71 to 90 (class III) may benefit from brief hospitalization, while inpatient care is appropriate for patients with a score greater than 90 (class IV and V). Prospective studies in both community and teaching hospitals demonstrate that the hospital admission decisions based on PSI may be safely and effectively applied in clinical practice.94, 95, 96 The PSI is complex and often needs decision support tools for efficient use in a busy emergency department.\n\neTable 33-2\n\nPatient CharacteristicPoints AssignedDEMOGRAPHIC FACTORSMalesAge (yr)FemalesAge (yr) − 10Nursing home residentsAge (yr) + 10COMORBID ILLNESSESNeoplastic disease+30Liver disease+20Congestive heart failure+10Cerebrovascular disease+10Renal disease+10PHYSICAL EXAMINATION FINDINGSAltered mental status+20Respiratory rate 30/min or greater+20Systolic blood pressure <90 mm Hg+20Temperature <35° C or ≥40° C+15Pulse 125/min or greater+10LABORATORY FINDINGSpH <7.35+30BUN >10.7 mmol/L+20Sodium <130 mEq/L+20Glucose >13.9 mmol/L+10Hematocrit <30%+10Po2 <60 mm Hg or O2 saturation <90%+10Pleural effusion+10\n\nAdapted from Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250, 1997.\n\nThe British Thoracic Society validated the simpler CURB-65 score for admission triage decisions.25, 97 Their algorithm assigns 1 point for each of the following findings at presentation: (1) confusion; (2) urea higher than 7 mmol/L (equal to BUN more than 20 mg/dL); (3) respiratory rate of 30/min or more; (4) low systolic (<90 mm Hg) or diastolic (≤60 mm Hg) blood pressure; and (5) age 65 years or older. Outpatient treatment is recommended for 0-1 points, brief inpatient or supervised outpatient care is recommended for 2 points, and hospitalization is recommended for 3 or greater, with consideration of ICU care for patients with scores of 4 or 5.\n\nRisk stratification for both PSI and CURB-65 was based on associated mortality. They are therefore not sensitive to logistic and social issues such as reliability of oral intake, including antibiotics, and home support.\n\nPatients initially admitted to a general floor with subsequent transfer to the ICU have higher mortality than patients with equivalent severity of illness admitted directly to the ICU.98 Neither PSI nor CURB-65 are accurate for determining need for ICU care in patients without an obvious indication such as the need for mechanical ventilation or vasopressor support while still in the emergency department. Several scores have been developed for this critical decision.58, 99, 100, 101 These scores share many common risk factors ( ) and appear to be equally effective,102 and management of severe CAP per these guidelines has been associated with decreased mortality.103, 104, 105 The optimal use of these scores is to identify at-risk patients who need additional evaluation or monitoring even if not initially admitted to the ICU.\n\nTable 33-7\n\nRespiratory rate > 30 breaths/min*†‡§Pao2/Fio2 ratio < 250 or arterial saturation ≤90% on room air*†‡§Multilobar or bilateral radiographic involvement or pleural effusion*†‡§Confusion or disorientation*†‡Uremia (BUN level > 20 mg/dL)*†‡Leukopenia (WBC count < 4000 cells/dL) or extreme leukocytosis (>20,000 cells/dL)*§Thrombocytopenia (platelet count < 100,000 cells/dL)*Hypothermia (core temperature < 36° C)*Hypotension requiring aggressive fluid resuscitation*Acidosis (pH < 7.30)†‡§Hypoalbuminemia (albumin < 3.5 g/dL)†Hyponatremia (sodium < 130 mEq/L)§Tachycardia (>125/min)†§\n\nSelection of Antimicrobial Agents\n\nWhenever possible, treatment for pneumonia should use the antibiotic with the narrowest spectrum possible, selected on the basis of the underlying pathogen. However, pathogens are rarely identified at the time of presentation, especially when pneumonia is managed in the outpatient setting. Because optimal outcomes are associated with a rapid initiation of antibiotics, initial treatment for patients with pneumonia must be empirical. In selecting initial empirical antimicrobial therapy, physicians should consider the setting in which the pneumonia arose (e.g., community, hospital, nursing home), the severity of illness, age of the patient, presence of comorbidities and immunosuppression, recent antimicrobial therapy, and specific clinical manifestations of the illness. Geographic and facility-specific factors, such as the local prevalence of specific microorganisms (e.g., C. burnetii, L. pneumophila, endemic mycoses, and multidrug-resistant [MDR] pathogens), may also affect the initial treatment choice.\n\nIn hospitalized patients, specimens for cultures of blood, sputum, and pleural fluid (if present) should be obtained before treatment. A brief delay in starting therapy while performing diagnostic procedures is reasonable in patients who are not hypotensive. However, delays of more than 4 to 8 hours may increase the length of hospitalization and have been associated with increased mortality.106, 107\n\nCommunity-Acquired Pneumonia\n\nThe standard therapy for inpatient empirical antibiotic coverage of CAP is one of two regimens: the combination of a second- or third-generation cephalosporin combined with a macrolide or one of the fluoroquinolones with efficacy against respiratory pathogens (levofloxacin, moxifloxacin, gatifloxacin).58 Either therapy should be effective against penicillin-resistant S. pneumoniae.108 The North American guidelines20, 21, 58 recommend that any empirical regimen for CAP should be active against “atypical” pathogens such as M. pneumoniae, C. pneumoniae, and L. pneumophila. Retrospective analyses of patients hospitalized with CAP indicate that regimens that cover “atypical” pathogens and those that follow recommendations made by the ATS and the IDSA are associated with improved clinical outcomes.18, 20, 96, 109, 110 In contrast, some Northern European guidelines suggest atypical coverage is not needed unless patients have clinical features more common to atypical pathogens.97 It is important to recognize that all CAP treatment guidelines are based on broad epidemiologic considerations that may vary by location. Variation from these regimens should be based on specific epidemiologic or clinical characteristics that strongly suggest one of the less common CAP pathogens such as mixed aerobic-anaerobic flora due to aspiration or presence of gram-negative Enterobacteriaceae or P. aeruginosa in patients with specified risk factors.24, 111\n\nWhen tuberculosis is a possibility, fluoroquinolones should be used cautiously in CAP, because as little as 10 days of fluoroquinolone administration is sufficient to select for fluoroquinolone-resistant M. tuberculosis.112\n\nThe greatest factor to consider in the choice of regimens is a history of recent use of any of the agents.113 Widespread fluoroquinolone use, especially in subtherapeutic doses, and use of ciprofloxacin has been associated with fluoroquinolone resistance in up to 13% of S. pneumoniae isolates in Hong Kong.114 Fluoroquinolone resistance and subsequent treatment failures are reported in pneumococcal CAP,114, 115, 116 but this is less common with use of the fluoroquinolones that have improved activity against respiratory pathogens. In contrast, the frequency of macrolide resistance in S. pneumoniae is increasing, and a macrolide should not be used for monotherapy of S. pneumoniae infection unless in vitro testing confirms that the patient's strain is susceptible to macrolides.\n\nEmpirical antibiotic treatment of severe CAP (SCAP) remains controversial, predominantly due to a lack of treatment studies specifically focused on SCAP. The spectrum of etiologies is clearly greater in SCAP. Even so, penicillin-sensitive pneumococci are still the most likely etiology. Whether SCAP justifies more aggressive diagnostic testing or broader spectrum empirical treatment in all cases has not been established. Retrospective studies suggest combination therapy specifically for severe pneumococcal pneumonia and for SCAP in general are associated with lower mortality. In a large cohort of older patients with CAP needing hospitalization, antibiotic treatment including azithromycin was associated with a lower 90-day risk mortality compared with other antibiotics.116a\n\nSummaries of the recent IDSA/ATS guideline CAP antibiotic recommendations are presented in and , respectively.58\n\neTable 33-3\n\nBRITISH THORACIC SOCIETY\n\nPrimary: amoxicillin\n\nAlternatives: erythromycin or clarithromycin\n\nAMERICAN THORACIC SOCIETY\n\nNo modifying factors*, #: Advanced macrolide† or doxycycline‡\n\nComorbidities*, #: β-lactam§ macrolide‖ or doxycycline,‡ or fluoroquinolone¶ alone\n\nINFECTIOUS DISEASES SOCIETY OF AMERICA\n\nNo modifying factors*, #: advanced macrolide† or doxycycline\n\nComorbidities*, #: fluoroquinolone¶ or advanced macrolide†\n\nAntibiotics within 3 months: fluoroquinolone¶ alone or advanced macrolide† β-lactam§\n\nSuspected aspiration: clindamycin or amoxicillin-clavulanate\n\nInfluenza with bacterial superinfection: β-lactam§ or fluoroquinolone¶\n\nNursing home patient: fluoroquinolone¶ alone, or amoxicillin-clavulanate advanced macrolide\n\nDRUG-RESISTANT STREPTOCOCCUS PNEUMONIAE THERAPEUTIC WORKING GROUP\n\nPrimary: macrolide, doxycycline, cefuroxime, amoxicillin, amoxicillin-clavulanate\n\nAlternative: fluoroquinolone#\n\nCANADIAN INFECTIOUS DISEASES SOCIETY AND CANADIAN THORACIC SOCIETY\n\nNo modifying factors: macrolide or doxycycline‡\n\nCOPD: advanced macrolide† or doxycycline‡\n\nCOPD plus recent antibiotics or steroids: fluoroquinolone¶ alone, amoxicillin-clavulanate macrolide,‡ or second-generation cephalosporin** macrolide‡\n\nSuspected aspiration: amoxicillin-clavulanate macrolide, or fluoroquinolone‡ ¶ clindamycin, or metronidazole\n\nNursing home patient: fluoroquinolone# alone or macrolide‡ plus amoxicillin-clavulanate or second-generation cephalosporin\n\neTable 33-4\n\nMILD TO MODERATE DISEASE\n\nBritish Thoracic Society\n\nPrimary: ampicillin or penicillin plus a macrolide\n\nAlternative: fluoroquinolone*\n\nAmerican Thoracic Society\n\nNo modifying factors†: azithromycin alone, doxycycline, β-lactam, or fluoroquinolone* alone\n\nWith modifying factors‡: cefotaxime or ceftriaxone or ampicillin-sulbactam or high-dose ampicillin; macrolide or doxycycline; or fluoroquinolone* alone\n\nInfectious Diseases Society of America\n\nPrimary§: cefotaxime, ceftriaxone, ertapenem, or ampicillin/sulbactam plus advanced macrolide†; or fluoroquinolone* alone\n\nSuspected aspiration: fluoroquinolone* ± antianaerobic agent‖\n\nDrug-Resistant Streptococcus pneumoniae Therapeutic Working Group\n\nPrimary: cefuroxime, cefotaxime, ceftriaxone, or ampicillin-sulbactam; macrolide\n\nAlternative: fluoroquinolone*\n\nCanadian Infectious Diseases Society and Canadian Thoracic Society\n\nFluoroquinolone* or cephalosporin,¶ macrolide**\n\nSEVERE DISEASE\n\nBritish Thoracic Society\n\nPrimary: cefuroxime, cefotaxime, or ceftriaxone; macrolide, rifampin\n\nAlternative: fluoroquinolone* ± penicillin IV\n\nAmerican Thoracic Society\n\nStandard: cefotaxime or ceftriaxone; azithromycin or fluoroquinolone*\n\nAt risk for Pseudomonas aeruginosa ††: antipseudomonal β-lactam‡‡ ciprofloxacin or antipseudomonal β-lactam aminoglycoside plus azithromycin or fluoroquinolone*\n\nInfectious Diseases Society of America\n\nPrimary: cefotaxime, ceftriaxone, ertapenem, or ampicillin/sulbactam; advanced macrolide† or fluoroquinolone*\n\nβ-Lactam allergy: fluoroquinolone* ± clindamycin\n\nPseudomonas risks††: antipseudomonal β-lactam‡‡ ciprofloxacin or antipseudomonal β-lactam‡‡ aminoglycoside; fluoroquinolone* or a macrolide\n\nPseudomonas risks†† and β-lactam allergy: aztreonam levofloxacin or aztreonam; moxifloxacin or gatifloxacin ± an aminoglycoside\n\nDrug-Resistant Streptococcus pneumoniae Therapeutic Working Group\n\nPrimary: ceftriaxone or cefotaxime, macrolide; or ceftriaxone or cefotaxime, fluoroquinolone*\n\nAlternative (with caution): fluoroquinolone*\n\nCanadian Infectious Diseases Society and Canadian Thoracic Society\n\nStandard: cefotaxime, ceftriaxone or β-lactam/β-lactamase inhibitor; fluoroquinolone* or macrolide**\n\nPseudomonas risks††: ciprofloxacin, antipseudomonal β-lactam‡‡ or aminoglycoside or antipseudomonal β-lactam‡‡ aminoglycoside macrolide**\n\nHospital-Acquired Pneumonia and Ventilator-Associated Pneumonia\n\nEmpirical therapy for VAP is necessarily broad because the range of potential pathogens is large and mortality is increased when the responsible pathogen is resistant to the initial empirical antibiotic regimen ( ). Recommended empirical regimens include expanded-spectrum β-lactam agents, usually in combination with aminoglycosides and with MRSA coverage.53 The empirical β-lactam should be based on antibiotic sensitivity patterns for common gram-negative pathogens in the relevant institution or specific unit.\n\nTable 33-8\n\nSettingCore PathogensAntimicrobial Choices2 to 5 Days in HospitalMild to moderate pneumonia†\n\nSevere pneumonia “low-risk”†Enterobacteriaceae\n\nStreptococcus pneumoniae\n\nHaemophilus influenzae\n\nMethicillin-sensitive\n\nStaphylococcus aureusβ-Lactam/β-lactamase inhibitor‡or ceftriaxone or fluoroquinolone§\n\nAll ± an aminoglycoside≥5 Days in HospitalMild to moderate pneumoniaAs aboveAs above≥5 Days in HospitalSevere HAP “low risk”Pseudomonas aeruginosa\n\nEnterobacter spp.\n\nAcinetobacter spp.Carbapenem or β-lactam/βl-lactamase inhibitor†or cefepimeAll plus amikacin or fluoroquinolone§≥2 Days in HospitalSevere HAP “high risk”As aboveAs aboveSpecial Circumstances19, 58Recent abdominal surgery or witnessed aspirationAnaerobesAs per Other sites of infection with MRSA or prior use of antistaphylococcal antibioticsMRSAAs per Prolonged ICU stay or prior use of broad-spectrum antibiotics or structural lung disease (cystic fibrosis, bronchiectasis)P. aeruginosaAs per Endemicity within facility and either impaired cell-mediated immunity or failure to respond to antibioticsLegionellaAs per\n\nModified from American Thoracic Society: Hospital-acquired pneumonia in adults: Diagnosis assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 153:1711–1725, 1995.\n\nEmpirical antibiotics for HAP are less well studied. HAP in nonintubated patients is a mixture of CAP pathogens and the pathogens found in VAP, although the frequency of the latter is likely lower, especially in cases that present early after admission. The greatest risk for MDR pathogens in nonintubated patients with HAP is recent antibiotic therapy, and monotherapy is probably adequate for most patients without recent antibiotic exposure. Anaerobes appear to play a slightly greater role in HAP than VAP because of the risk of macroaspiration, but specific anaerobic coverage is not necessary if an appropriate β-lactam is used. Unless Legionella is known to be endemic in the institution, targeted therapy for this pathogen is seldom necessary in the empirical treatment of HAP. Efforts to identify the cause of infection are especially crucial in patients with HAP or VAP, to allow selection of optimal antimicrobial therapy and minimize the duration of empirical broad-spectrum coverage.\n\nHealth Care–Associated Pneumonia\n\nThe optimal approach to empirical coverage for HCAP remains controversial, due to variations in health care systems and definitions.55, 117, 118, 119 Pneumonia in nursing home and chronic care facility residents is seen in a bimodal pattern. Ambulatory patients who are able to take care of most of their activities of daily living have disease that resembles CAP,29 while in contrast, severely debilitated patients with tracheostomies, feeding tubes, frequent and recent acute care hospital admissions, and frequent exposure to antibiotics are at high risk for MDR pathogens and should be treated with VAP regimens. Culture-negative HCAP patients have equivalent or better outcomes when treated with CAP antibiotics as with broader spectrum treatment,119 but are difficult to identify at admission. If started on broader therapy, deescalation to CAP therapy after culture results return negative appears safe.120\n\nOther Pneumonia Syndromes\n\nOn initial presentation, a variety of other infectious pulmonary syndromes may not be readily differentiated from acute bacterial pneumonia. Examples include influenza A, severe acute respiratory syndrome,49, 50 hantavirus pulmonary syndrome, and other viral pneumonias. Milder cases of viral pneumonia may be distinguished by a low PCT level and antibiotics can be safely withheld or withdrawn in these patients.121\n\nConcerns about potential bioterrorism or biowarfare require attention to the epidemiologic, clinical, and microbiologic significance of pneumonia due to B. anthracis (anthrax),51 F. tularensis (tularemia),52 and Y. pestis (plague). These infectious agents are individually discussed later in this chapter. Further information may be obtained from organizations such as the Centers for Disease Control and Prevention (www.cdc.gov ), IDSA (www.idsociety.org), and the World Health Organization (www.who.org) (see Chapter 40).\n\nAdjustments in Antimicrobial Therapy\n\nIf the etiologic agent of a patient's pneumonia has been identified, the initial antimicrobial regimen should be adjusted based on the results of in vitro susceptibility testing. The ideal drug for a known pathogen has the narrowest spectrum of activity and is the most efficacious, least toxic, and least costly. Pathogen-based modification of therapy is particularly important in HAP because prolonged use of broad-spectrum empirical agents promotes the emergence of MDR pathogens. Recommendations for specific drug choices for specific microorganisms are discussed under the sections devoted to individual microorganisms and are summarized in . If a pathogen is not identified, reevaluation of the initial therapeutic regimen must take into account the patient's response to therapy. Change from parenteral to oral antimicrobial therapy can safely be made in hospitalized CAP patients when clinically stable and able to absorb effective oral antimicrobials122, 123; this is often achieved within 3 days. In-hospital observation after switching from intravenous to oral antibiotics for CAP patients is not needed. Because HAP pathogens are frequently resistant to available oral antimicrobials, enteral absorption is less predictable, and the severity of illness is greater, initial oral antimicrobial therapy is much less frequently appropriate.\n\nTable 33-9\n\nType of InfectionPreferred Agent(s)Alternative Agent(s)COMMUNITY-ACQUIRED PNEUMONIAStreptococcus pneumoniae PCN-susceptiblePenicillin G, amoxicillin, clindamycin, doxycyclineCephalosporin, macrolide,* (MIC < 2 g/mL) fluoroquinolone† PCN-resistantAgents identified using in vitro susceptibility tests, including cefotaxime, ceftriaxone, vancomycin, and fluoroquinolone†Macrolide, if susceptibleMycoplasmaDoxycycline, macrolideFluoroquinolone†Chlamydophila pneumoniaeDoxycycline, macrolideFluoroquinolone†LegionellaAzithromycin, fluoroquinolone (including ciprofloxacin),† erythromycin (± rifampin)Doxycycline ± rifampinHaemophilus influenzaeSecond- or third-generation cephalosporin, clarithromycin, doxycycline, β-lactam/β-lactamase inhibitor, trimethoprim-sulfamethoxazole, azithromycinFluoroquinolone†Moraxella catarrhalisSecond- or third-generation cephalosporin, trimethoprim-sulfamethoxazole, macrolide doxycycline, β-lactam/β-lactamase inhibitorFluoroquinolone†Neisseria meningitidisPenicillinCeftriaxone, cefotaxime, cefuroxime, chloramphenicol, fluoroquinolone†Streptococci (other than S. pneumoniae)Penicillin, first-generation cephalosporinClindamycin (susceptibility should be confirmed), vancomycinAnaerobesClindamycin, β-lactam/β-lactamase inhibitor, β-lactam plus metronidazoleCarbapenemStaphylococcus aureus Methicillin-susceptible‡Oxacillin, nafcillin, cefazolin; all ± rifampin or gentamicin‡Cefuroxime, cefotaxime, ceftriaxone, fluoroquinolones,† clindamycin, vancomycin Methicillin-resistant‡Vancomycin‡ ± rifampin or gentamicinLinezolid, quinupristin-dalfopristin; trimethoprim-sulfamethoxazole, fluoroquinolones,† and tetracyclines may also show activity (in vitro testing required)Klebsiella pneumoniae and other Enterobacteriaceae (excluding Enterobacter spp.)Third-generation cephalosporin or cefepime (all ± aminoglycoside) carbapenemAztreonam, β-lactam/β-lactamase inhibitor,§ fluoroquinolone†HOSPITAL-ACQUIRED INFECTIONSEnterobacter spp.Carbapenem, β-lactam/β-lactamase inhibitor, cefepime, fluoroquinolone; all + aminoglycoside in seriously ill patientsThird-generation cephalosporin + aminoglycosidePseudomonas aeruginosaAntipseudomonal β-lactam§ + aminoglycoside, carbapenem + aminoglycosideCiprofloxacin + aminoglycoside, ciprofloxacin + antipseudomonal β-lactam‖AcinetobacterAminoglycoside + piperacillin or a carbapenemDoxycycline, ampicillin-sulbactam, colistinLESS COMMON PATHOGENSNocardiaTrimethoprim-sulfamethoxazoleImipenem ± amikacin, doxycycline or minocycline, sulfonamide ± minocycline or amikacinCoxiella burnetii (Q fever)DoxycyclineFluoroquinoloneChlamydophila psittaci (psittacosis)DoxycyclineErythromycin, chloramphenicolEikenella corrodensPenicillinTetracyclines, β-lactam/β–lactamase inhibitor, second- and third-generation cephalosporins, fluoroquinolones\n\nModified from Bartlett JG, Dowell SF, Mandell LA, et al: Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 31:347−382, 2000.\n\nCommon Causes of Pyogenic Pneumonia\n\nIndividual pneumonia pathogens may have unique epidemiology, diagnostic tests, and/or treatment. The sections that follow emphasize these unique aspects for selected pathogens (or groups).\n\nStreptococcus pneumoniae (Pneumococcal Pneumonia)\n\nEpidemiology\n\nS. pneumoniae is the most frequent cause of CAP among patients who require hospitalization.21, 22 The overall incidence of pneumococcal pneumonia is approximately 200 cases per 100,000 persons per year, with 9 to 14 cases per 100,000 cases of bacteremia. This infection accounts for 40,000 deaths annually in the United States with most deaths in the very young and the elderly. Risk factors, particularly in adults, include cigarette smoking, HIV infection (even with preserved CD4 counts), heavy alcohol use, chronic liver disease, genetic defects in host immunity, and malnutrition.124, 125 Pneumococcal infections present predominantly in the winter and early spring and are often associated with prior infection by influenza or respiratory syncytial virus.126\n\nUse of the conjugate pneumococcal vaccine has markedly decreased invasive pneumococcal infections in children, with a secondary reduction in adults.127, 127a This latter effect probably represents interruption of transmission by aerosolized droplets and direct physical contact, in that the conjugate vaccine is effective in blocking colonization.128 However, widespread use of the conjugate vaccine in the United States has resulted in an increase in the number and proportion of cases of invasive pneumococcal disease due to isolates with polysaccharide capsule types that are not included in the seven-valent vaccine.129 Consequently, a conjugate vaccine containing 13 capsular polysaccharide antigens was developed; this was approved by the U.S. Food and Drug Administration in 2012.\n\nClinical Manifestations\n\nThe classic presentation of pneumococcal pneumonia consists of a single rigor followed by sustained fever, cough, dyspnea, and production of rusty or mucoid sputum; gross hemoptysis is unusual. Severe pleuritic chest pain is common. The radiographic appearance of pneumococcal pneumonia is often either lobar consolidation (see and ) or patchy bronchopneumonia ( ). Although pneumococci can cause necrotizing pneumonia, cavitation rarely develops.125 Small, parapneumonic effusions are frequently found and can progress to frank empyema. Neutropenia may develop in patients with overwhelming infection.\n\nMicrobiologic Diagnosis\n\nAlthough Gram stain of purulent sputum that reveals numerous, characteristic “lancet-shaped” diplococci with blunted ends (commonly seen in pairs and short chains) in the absence of other predominant flora is strongly suggestive of pneumococcal pneumonia ( ), a good quality sputum specimen cannot always be obtained.130 The organism is recovered from sputum culture in fewer than half of cases, and even a single dose of antibiotics can affect the yield of sputum cultures, which contributes to the discrepancy between sputum Gram stain and culture results. The frequency of positive blood cultures has fallen from 30% of hospitalized patients20 to less than 10% in many contemporary series. This decrease may reflect a greater percentage of blood cultures drawn after antibiotics because of the emphasis on timely antibiotic doses in the emergency department, deemphasis on blood cultures in CAP in general, and/or a benefit of vaccination on invasive pneumococcal disease.\n\nThe rapid urinary antigen S. pneumoniae test offers an alternative approach to the diagnosis of pneumococcal CAP and is becoming more widely used in diagnosis and in narrowing antibiotic therapy.74, 75, 77, 131 Despite satisfactory sensitivity and specificity, the urinary antigen test is complementary to culture methods, since it cannot provide information on antimicrobial susceptibility of the infecting organism.\n\nClinical Course\n\nWith an appropriate antibiotic, a clinical response is usually expected within 24 to 48 hours. The onset of suppurative complications, such as purulent pericarditis, meningitis, endocarditis, arthritis, and cellulitis after initiation of therapy is uncommon in the modern era. The exception is empyema, which appears to be increased due to serotype replacement in the vaccinated populations by serotypes more often associated with empyema.132 Pneumococcal pneumonia remains a cause of septic shock and ARDS.133\n\nTreatment\n\nAntimicrobial resistance complicates treatment for S. pneumoniae in much of the world, including in the United States.134 For nonmeningeal isolates of S. pneumoniae, the redefinition of full susceptibility as a minimum inhibitory concentration (MIC) of penicillin less than or equal to 2 µg/mL and high-level resistance as MIC greater than or equal to 8 µg/mL markedly changed the incidence of penicillin resistance.135 This redefinition was driven by discordance between the previous lower MIC breakpoints and clinical success rates. The rate of increase in the frequency of penicillin resistance may have stabilized, possibly as a consequence of the pneumococcal conjugate vaccine and a shift in the outpatient antibiotic prescription patterns away from β-lactams.136\n\nPenicillin resistance in S. pneumoniae is due to alterations in penicillin-binding proteins rather than to β-lactamase production. Unlike other β-lactams, cefotaxime, ceftriaxone, and cefepime retain activity against 75% to 95% of nonmeningeal isolates of S. pneumoniae. 137 S. pneumoniae resistance rates to other antimicrobials can be as high as 30% for trimethoprim-sulfamethoxazole (TMP-SMX), 16% for tetracyclines, 26% for macrolides, and 9% for clindamycin; these rates are higher among penicillin-resistant pneumococci.134, 136 High-level macrolide resistance (MIC > 64 µg/mL) associated with the MLSB (macrolide, lincosamide, streptogramin B) phenotype is more common in Europe138 and has been associated with in vitro resistance to clindamycin.139 S. pneumoniae resistance to fluoroquinolones has also emerged with associated clinical treatment failures.113, 136\n\nRecent exposure to an antibiotic increases the likelihood of the patient having a pneumococcal isolate resistant to that antibiotic (or class of antibiotics). Thus, it is important to avoid antibiotics that have been used in the prior 90 days when selecting a regimen for empirical treatment of a pneumococcal infection.113 Retrospective and prospective observational studies have suggested a benefit to treating severely ill patients with proven pneumococcal infections with both a β-lactam and a macrolide.76, 140, 141 Explanations that have been proposed to explain those results include nonbactericidal effects, such as inhibiting biofilm production, or an anti-inflammatory effect of the macrolide.\n\nOther Streptococci\n\nEpidemiology\n\nS. pyogenes (group A β-hemolytic streptococcus) can be found in the oropharynx of more than 20% of children and a smaller percentage of adults. Carriage rates increase greatly during epidemics and in crowded conditions.128, 142 In the United States, the incidence of pneumonia due to S. pyogenes was 0.15 to 0.35 per 100,000 persons per year, but may be as high as 3.6 per 100,000 in children.143, 144 The organism is easily transferred between contacts, leading to epidemics of group A streptococcal pneumonia in military recruits, nursing homes, and other crowded settings.142 Pneumonia due to S. pyogenes most often manifests during the late winter and spring months, may follow an episode of influenza, measles, or varicella, and has been associated with increased age, alcohol abuse, diabetes mellitus, cancer, and HIV infection.143, 144 S. pyogenes can cause necrotizing pneumonia145 and is associated with pleural empyema.146\n\nGroup B (i.e., Streptococcus agalactiae) streptococci are a major cause of neonatal sepsis and pneumonia. In adults, pneumonia accounts for approximately 15% of adult infections by group B streptococci.147 Most adults with group B streptococcal pneumonia are debilitated and develop pneumonia as a consequence of aspiration.147 Diabetes, cirrhosis, stroke, decubitus ulcer, and neurogenic bladder are also risk factors.147\n\nThe Streptococcus milleri group C streptococci (which include S. intermedius, S. anginosus, and S. constellatus) have emerged as significant respiratory pathogens, predominantly causing empyema ( and Video 33-1 ) and lung abscesses as well as superinfection pneumonia in severe viral pneumonia.148, 149 Infections with bacteria in this group share many of the features of anaerobic infections, including increased risk with periodontal disease and alcoholism. Other viridans and microaerophilic streptococci (α-hemolytic, nonpneumococcal) are rarely the sole pathogens in patients with pneumonia; they are more commonly found mixed with other facultative and anaerobic organisms in aspiration pneumonia.\n\nClinical Manifestations\n\nCAP from these pathogens is clinically indistinguishable from pneumococcal pneumonia. Exudative pharyngitis may be evident and unilobar involvement is common with group A streptococcal pneumonia. Pleural effusions in group A streptococcal pneumonia are frequent, may be large, accumulate rapidly, and appear early in the course of the disease, particularly in children.148 Pneumonia caused by other β-hemolytic streptococci is usually less abrupt and milder; pleural effusions are uncommon, and lung tissue necrosis is rare despite frequent bacteremia.147 S. milleri infection is predominantly associated with empyema, with or without concomitant pneumonia.148 Pneumothorax at the time of initial presentation appears to be more common with S. milleri than with other streptococcal empyemas.\n\nMicrobiologic Diagnosis\n\nBecause streptococci are common in the oropharynx, documentation of infection from these organisms requires isolation from a culture of blood, pleural fluid, or respiratory specimen obtained by means of an invasive procedure ( ). Pleural fluid cultures of children with S. pyogenes pneumonia are frequently positive. Polymerase chain reaction technology holds promise for aiding diagnosis, especially of group A streptococcal infections150 and S. milleri empyema.149\n\nClinical Course\n\nEmpyema and/or pericarditis are seen in 5% to 30% of patients with group A streptococcal pneumonia143; other complications include pneumothorax, mediastinitis, and bronchopleural fistula formation. The only classic nonsuppurative complication that follows S. pyogenes pneumonia is glomerulonephritis.\n\nTreatment\n\nMost of these streptococci are susceptible to penicillin G, ampicillin, and many cephalosporins, although α-hemolytic streptococci may require high dosage, due to the phenomenon of tolerance (growth inhibition without killing, at low and intermediate drug concentrations). Because resistance to clindamycin and erythromycin is found in up to 15% to 20% of isolates, susceptibility testing is advisable before monotherapy with a macrolide or clindamycin.151 As for empyemas caused by other pathogens, drainage of empyema fluid is an important component of therapy.\n\nHaemophilus influenzae\n\nEpidemiology\n\nInvasive infection, especially pneumonia, due to H. influenzae is estimated to account for approximately 1.2 cases per 100,000 adults per year in the United States, and is one of the more common causes of pneumonia in adults requiring hospitalization. Chronic lung disease, malignancy, HIV infection, and alcoholism are among the most common predisposing conditions to Haemophilus pneumonia. Active smoking appears to particularly increase the risk of H. influenzae pneumonia.\n\nAs with S. pneumoniae, vaccination against H. influenzae type b significantly changed the epidemiology of childhood pneumonia.152 Vaccinated children are still susceptible to unencapsulated (or nontypeable) strains but the incidence of H. influenzae pneumonia has fallen dramatically. Nonbacteremic infection by unencapsulated or non–type b strains is the most common form of H. influenzae pneumonia in adults.152\n\nClinical Manifestations\n\nHaemophilus pneumonia is clinically indistinguishable from other bacterial pneumonias ( ). On radiographs, Haemophilus pneumonia may be multilobar, patchy bronchopneumonia or have areas of frank consolidation. Spherical radiographic opacities (so-called round pneumonia) have been described, but cavitation is uncommon. Small parapneumonic effusions may occasionally progress to empyema. Bacteremia is more common in children than in adults.\n\nMicrobiologic Diagnosis\n\nDiagnosing H. influenzae pneumonia by a Gram stain of sputum is difficult, because the small, pleomorphic coccobacilli are often overlooked. Culture of expectorated sputum reveals H. influenzae in only half of well-documented cases of pneumonia. Asymptomatic colonization with nontypeable strains in patients with COPD complicates analysis of Gram stain and sputum cultures ( ).\n\nClinical Course\n\nThe overall mortality rate of H. influenzae pneumonia is 5% to 7% but is higher in patients with bacteremia or extrapulmonary disease.152 Associated foci of infection, such as empyema, meningitis, arthritis, pericarditis, and epiglottitis are more common with encapsulated (type b) H. influenzae.\n\nTreatment\n\nH. influenzae isolates produce β-lactamase in 20% to 50% of cases and are therefore resistant to ampicillin. Increasing macrolide resistance also compromises empirical therapy with these agents. Consequently, serious H. influenzae respiratory tract infections should be treated with a second- or third-generation cephalosporin, β-lactam/β-lactamase inhibitor, or fluoroquinolone while awaiting results of susceptibility testing.\n\nMycoplasma pneumoniae\n\nEpidemiology\n\nM. pneumoniae accounts for up to 37% of CAP in persons treated as outpatients and 10% of pneumonias requiring hospitalization.20, 22 In the United States, there is an estimated 2 cases per year per 1000 individuals. Mycoplasma infections are seen throughout the year, but outbreaks are most common in the fall. Because Mycoplasma is readily transmitted from person to person via aerosolized respiratory droplets, outbreaks are common in families or closed populations.153\n\nClinical Manifestations\n\nThe clinical picture of M. pneumoniae pneumonia is the paradigm of atypical CAP,18, 21 as described previously. Pharyngitis, cervical adenopathy, and bullous myringitis may be encountered, although the latter is not more common with Mycoplasma pneumonia than with pneumococcal pneumonia/otitis. A wide variety of exanthems, including maculopapular eruptions, urticaria, erythema multiforme, and erythema nodosum, develop in 10% to 25% of patients. The chest radiograph usually shows an interstitial or a mixed pattern that may be more striking than expected based on chest physical findings ( and ). Other chest radiographic patterns are occasionally encountered as well ( ).\n\nMicrobiologic Diagnosis\n\nWhen obtained, sputum generally displays moderate numbers of polymorphonuclear leukocytes without a predominant organism. Recovery of M. pneumoniae from culture of clinical specimens requires special media and takes approximately 10 days. Although acute Mycoplasma pneumonia may stimulate cold agglutinin production in a titer of 32 or greater, this nonspecific result is also found in various other infectious and noninfectious conditions including pneumonia due to Legionella, adenovirus, and influenza.18 The shortcomings of staining, culture, and serology for detection of Mycoplasma pneumoniae make this pathogen especially suitable for diagnosis by nucleic acid testing. Several nucleic acid tests for M. pneumoniae are currently available, and their role in management of CAP is being defined (see Chapter 17).\n\nClinical Course\n\nMycoplasma pneumonia is usually a benign, often self-limited infection with an excellent prognosis for complete recovery. ARDS and death have been reported but are rare. A unique aspect of M. pneumoniae infection is the frequency of associated autoimmune disorders including fulminant autoimmune hemolytic anemia, Stevens-Johnson syndrome, aseptic meningitis, meningoencephalitis, pericarditis, and myocarditis.154\n\nTreatment\n\nAntimicrobial therapy with a tetracycline, macrolide, or fluoroquinolone shortens the course of clinical symptoms and hastens resolution of radiographic abnormalities. To prevent clinical relapse, 2 weeks is the minimum recommended duration for treatment.18 Respiratory isolation can limit transmission, and azithromycin prophylaxis can prevent infection in close contacts of patients.155\n\nChlamydophila pneumoniae\n\nEpidemiology\n\nC. pneumoniae (formerly Chlamydia pneumoniae) accounts for 5% to 15% of cases of CAP.22 Seroepidemiologic studies suggest that C. pneumoniae eventually causes infection in 40% to 50% of the general population.\n\nClinical Manifestations\n\nPrimary infection by C. pneumoniae is usually asymptomatic: an acute, mild respiratory tract infection is observed in only 10% of infected adolescents and young adults.156 There may be bronchitis, sinusitis, laryngitis, tonsillitis, or exacerbations of asthma, with or without associated pneumonia. Sore throat with hoarseness is often severe and may precede pneumonia by up to a week and resolve before pneumonia onset, resulting in a biphasic illness. The erythrocyte sedimentation rate is elevated, but leukocytosis or elevated PCT may be absent.\n\nMicrobiologic Diagnosis\n\nC. pneumoniae cannot be visualized by Gram stain, and tissue culture is required to grow the pathogen. Although direct fluorescent antibody detection of C. pneumoniae is available, nucleic acid testing is emerging as a rapid, sensitive mode of detection that yields results in a time frame useful for clinical management (see Chapter 17).\n\nClinical Course and Treatment\n\nComplete recovery following C. pneumoniae infection is the rule; fatalities are principally seen in patients with mixed infection and preexisting illness.156, 157 When associated with an exacerbation of asthma, C. pneumoniae can require a prolonged time for recovery. Two-week treatment with a macrolide, tetracycline, doxycycline, or fluoroquinolone is recommended.18, 157 Older adults can be reinfected, often with severe symptoms.\n\nStaphylococcus aureus\n\nEpidemiology\n\nS. aureus accounts for less than 10% of cases of CAP,21 but is the second or third most common etiology in patients with CAP requiring ICU admission. S. aureus, especially MRSA, accounts for up to 30% of nosocomial pneumonias.29 Nasal colonization is the major source for pneumonia and other invasive S. aureus infections: 30% to 50% of healthy adults carry the organism transiently in the anterior nares. Health care workers may have even higher carriage rates. Although the organism is easily transferred from person to person by direct hand contact, 67% of patients in whom MRSA pneumonia develops have nasal colonization on admission, indicating that most cases of S. aureus HAP are not due to S. aureus transmission in the hospital.158\n\nA community-acquired strain of MRSA (CA-MRSA) has become an important CAP pathogen.159, 160, 161, 162 In addition to antibiotic resistance, the DNA cassette containing the mecA gene that confers methicillin resistance to this strain includes other virulence factors. The combination of antibiotic resistance and multiple virulence factors is associated with significantly higher mortality.163 Typical hospital-acquired strains of MRSA also cause CAP but usually in patients with risk factors for HCAP.164 The ability to differentiate clinically between hospital- and community-acquired cases is increasingly difficult because risk factors, such as prior antibiotic therapy, often overlap.\n\nFactors that predispose patients to acquire staphylococcal pneumonia include underlying pulmonary disease (e.g., COPD, carcinoma, cystic fibrosis), chronic illness (e.g., diabetes mellitus, renal failure), or viral infection (e.g., influenza, measles).165 S. aureus, including CA-MRSA, is second in frequency to S. pneumoniae as a cause of postinfluenza bacterial pneumonia. Postinfluenza CAP due to CA-MRSA is associated with a high frequency of complications and mortality. Pneumonia due to hematogenous spread of S. aureus is a unique type of pneumonia, usually a consequence of intravenous drug use or septic embolization from endocarditis or an infected vascular site.\n\nClinical Manifestations\n\nCA-MRSA pneumonia can be seen in young patients without underlying illnesses. The clinical presentation in severe cases includes high fever, hypotension, and hemoptysis with rapidly progressive deterioration and septic shock. Leukopenia, rather than leukocytosis, is observed in a substantial fraction of cases and is associated with poor outcomes.159, 161, 165 The radiographic features of CA-MRSA pneumonia include multilobar opacities and/or cavitary lesions ( ).\n\nIn cases acquired hematogenously such as in endocarditis or other endovascular infection, signs and symptoms related to the underlying endovascular infection predominate; if pulmonary infarction results from a septic embolism, pleuritic chest pain and hemoptysis are often noted. Otherwise, respiratory tract symptoms are mild or absent. The chest radiograph in patients with hematogenous staphylococcal pneumonia often reveals multiple, discrete, and often cavitary shadows with a predilection for the lower lobes ( ).166\n\nMicrobiologic Diagnosis\n\nPurulent sputum with multiple clusters of large gram-positive cocci, particularly if intracellular, is strongly suggestive of S. aureus pneumonia ( ). The organism is easily recovered from sputum cultures. Absence of MRSA on culture, even after several doses of antibiotics, is strong evidence that MRSA is not the causative pathogen. Fewer than 15% of pneumonias due to aspiration are associated with positive blood cultures. In contrast, hematogenous staphylococcal pneumonia usually yields multiple positive blood cultures. CA-MRSA pleural effusions are often exudative rather than grossly purulent but are still high yield on culture. An important clue to CA-MRSA is the presence of skin lesions,167 which are often positive on Gram stain as well.\n\nClinical Course\n\nEven with appropriate antibiotics, the duration of fever and need for ICU care is often prolonged for S. aureus pneumonia, particularly CA-MRSA. Local complications of staphylococcal pneumonia include empyema and abscess formation. Infection can spread hematogenously to the central nervous system, bones, joints, skin, and kidneys. Cavities and necrotic tissue may prevent adequate local antibiotic penetration, whereas unrecognized or incompletely drained empyema may prolong fever. Most of these manifestations are due to strains secreting Panton-Valentine leukocidin or one of the other exotoxins produced by S. aureus. Pleuroscopy or decortication is required in a large percentage of cases with empyema.\n\nThe mortality of S. aureus CAP is generally higher than most etiologies, with the mortality in methicillin-sensitive strains about 30%. S. aureus CAP following influenza has a reported mortality of greater than 60%, even if not methicillin-resistant.16\n\nTreatment\n\nThe treatment of choice for methicillin-susceptible S. aureus pneumonia is a penicillinase-resistant penicillin (e.g., oxacillin 8 to 12 g/day) or a first-generation cephalosporin. Therapy for 7 to 10 days is adequate in uncomplicated cases, but 4 to 6 weeks of treatment is recommended for patients with bacteremia or cavitation. In the penicillin-allergic patient, clindamycin or linezolid can be used.\n\nTreatment of MRSA pneumonia is more challenging, and the incidence of CAP caused by both health care–associated MRSA and CA-MRSA strains is increasing. Although resistance to vancomycin is still rare, the MIC has been shifting upward and MICs greater than 1 µg/mL have been associated with clinical failure. In higher-risk patients, such as those with VAP or with underlying renal insufficiency, linezolid has been found to have better clinical response rates than vancomycin, although differences in patient survival have been variable.168, 169, 170 For CA-MRSA, vancomycin therapy alone has been associated with a significant failure rate.160, 163 Addition of clindamycin or use of linezolid has been associated with improved outcomes in small case series. Unlike in MRSA skin infections, clindamycin, fluoroquinolones, and TMP-SMX are unreliable in severe CA-MRSA cases. Daptomycin is ineffective for treatment of pneumonia, because it binds to and is inactivated by pulmonary surfactant.171\n\nGram-Negative Bacillary Pneumonia\n\nThe term gram-negative bacillary pneumonia refers to infections caused by members of two groups, the Entero­bacteriaceae and Pseudomonadaceae and other aerobic gram-negative bacilli. Infections caused by Haemophilus, Legionella, and anaerobes are usually excluded from this categorization.\n\nEnterobacteriaceae\n\nEpidemiology.\n\nWhile they are more common as causes of HAP, gram-negative bacilli may cause up to 5% to 10% of CAP.21, 24, 111 CAP due to gram-negative bacilli is often severe and frequently requires ICU care. Patients in an ICU, especially those undergoing mechanical ventilation, have the highest risk for development of gram-negative bacillary pneumonia.\n\nThe Enterobacteriaceae normally colonize the digestive tract, and pneumonia usually results from aspiration of oropharyngeal flora. Although uncommon in healthy, nonhospitalized individuals, oropharyngeal colonization by gram-negative bacilli is greatly increased by hospitalization and antimicrobial use; the risk for aspiration is increased by comorbidities, such as cerebrovascular accidents, seizures, or anesthesia.24 Occasionally, contaminated home respiratory therapy equipment directly introduces gram-negative rods into the respiratory tract. Finally, Enterobacteriaceae pneumonia may result from hematogenous seeding from infection at other anatomic sites.\n\nAmong the Enterobacteriaceae, Escherichia coli is the single most frequent cause of CAP.24 The classic cause of community-acquired gram-negative bacillary pneumonia, K. pneumoniae (Friedlander pneumonia), causes fewer than 10% of CAPs, but more than 20% of nosocomial pneumonias. Alcohol abuse is the most common underlying condition for community-acquired K. pneumoniae pneumonia. Other underlying conditions that predispose to Klebsiella infections are diabetes mellitus and COPD.\n\nClinical Manifestations.\n\nIn Klebsiella CAP, a syndrome of pleuritic chest pain, hemoptysis, and bloody sputum (occasionally with a “currant jelly” appearance) is classic but rarely seen. The clinical manifestations of Enterobacteriaceae pneumonias are not sufficiently unique to distinguish these infections from pneumonias due to other causes.24\n\nMost laboratory abnormalities are nonspecific, but neutropenia is associated with a poor prognosis. Chest radiographs often demonstrate lower lobe bronchopneumonia ( ), which is often bilateral. A classic radiographic appearance of Klebsiella pneumonia is upper lobe consolidation (especially on the right) ( ) with a bulging or bowed fissure. This manifestation is now uncommon. Klebsiella can also cause lung abscess ( ) in patients with HCAP.\n\nMicrobiologic Diagnosis.\n\nEnterobacteriaceae pneumonia should be suspected when sputum Gram stain reveals large numbers of uniform-appearing gram-negative rods ( ). Sputum culture alone is nonspecific for Enterobacteriaceae in either nonintubated or intubated patients because of oropharyngeal colonization and is one of the major reasons for interest in quantitative cultures as an approach to distinguishing colonization from infection.\n\nClinical Course.\n\nEnterobacteriaceae pneumonia fatality rates are 25% to 50%.24 Bacteremia, neutropenia, and advanced age contribute to a poor prognosis. Destruction of pulmonary alveolar septae may lead to cavitation.\n\nTreatment.\n\nTreatment of serious infections due to Enterobacteriaceae is complicated by widespread antimicrobial resistance. Extended-spectrum β-lactamase, carbapenemase, fluoroquinolone, and aminoglycoside resistance are all common in patients infected with Enterobacteraceae.172, 173 Due to regional and institutional variations in the frequency of resistance to specific drugs and classes of drugs, initial therapy of possible Enterobacteriaceae pneumonia must be selected using knowledge of local antibiotic resistance patterns. In patients with serious infection, a two-drug regimen of an aminoglycoside with a broad-spectrum β-lactam or carbapenem is recommended for treatment until susceptibility results are known. Monotherapy may be reasonable for immunocompetent patients with mild to moderate disease who are infected with susceptible strains of Proteus, Morganella, K. pneumoniae, or E. coli. Recommendations for empirical therapy for HAP are listed in , although local resistance patterns must be taken into account.\n\nPseudomonas aeruginosa and Related Organisms\n\nEpidemiology.\n\nP. aeruginosa is an uncommon cause of CAP except in specific risk groups. Although one large study in Spain found that 7% of CAP was due to P. aeruginosa, most studies have found substantially lower rates.24, 111 One major risk factor for Pseudomonas CAP is structural lung disease, such as cystic fibrosis, bronchiectasis, and severe COPD (forced expiratory volume in 1 second <30%). Another risk factor is HIV infection, especially with a marked deficiency of CD4+ T cells.174, 175, 176 Pseudomonas pneumonia in AIDS patients can be severe, with mortality rates as high as 50%, and be associated with cavitation, even when the patient has a profound CD4+ T-cell deficiency. The incidence of Pseudomonas pneumonia has decreased with widespread availability of combination antiretroviral therapy. Pseudomonas pneumonia is rare in normal hosts, but it can develop after exposure to aerosols of contaminated water such as in hot tubs.21, 24, 40, 68, 177, 178\n\nP. aeruginosa is a leading cause of nosocomial pneumonia and a particularly frequent cause of VAP.179 Prolonged endotracheal intubation and prior antibiotic therapy, especially with broad-spectrum antibiotics, are major risk factors for Pseudomonas VAP. Other nonfermenters, such as S. maltophilia and B. cepacia, cause pneumonia in patients after prolonged broad-spectrum antibiotic therapy, and are associated with a high mortality rate. B. cepacia is also found in outpatients with cystic fibrosis.\n\nClinical Manifestations.\n\nThe clinical picture of pneumonia due to P. aeruginosa ( ) is indistinguishable from that of the Enterobacteriaceae. Bacteremia is slightly more common than for other gram-negative pathogens; physical examination may reveal ecthyma gangrenosum, and leukopenia is common. Its propensity to invade vascular tissue makes Pseudomonas the most common cause of cavitary pneumonia ( and ) in hospitalized or immunocompromised patients, and empyema can develop.\n\nMicrobiologic Diagnosis.\n\nGram-stained sputum from patients with Pseudomonas pneumonia typically shows many slender, gram-negative bacilli ( ); neutrophils are commonly abundant in the sputum except in neutropenic patients. Since Pseudomonas and other gram-negative bacilli colonize the oropharynx in hospitalized or debilitated patients, Gram stain results in these patients can be misleading. In endotracheally intubated patients, the absence of Pseudomonas on culture is strong evidence against Pseudomonas as the cause of the patient's pneumonia, because the organism is typically easy to recover.\n\nClinical Course.\n\nMortality from community-acquired P. aeruginosa pneumonia can exceed 25%,24 and in persons with VAP due to P. aeruginosa, mortality rates are 40% to 70%. The prognosis in neutropenic patients with P. aeruginosa pneumonia is particularly poor.180 P. aeruginosa VAP can recur in 25% to 50% of cases, approximately half due to a new strain.\n\nTreatment.\n\nP. aeruginosa pneumonia should initially be treated with two antimicrobial agents expected to be active against isolates in the region, such as an aminoglycoside and an antipseudomonal β-lactam antibiotic; this is especially true for bacteremic or neutropenic patients.180 Amikacin is the most reliably active aminoglycoside in most regions. The β-lactam antibiotics, in descending order of probable activity against P. aeruginosa, are the carbapenems (imipenem and meropenem), the acylureidopenicillins (e.g., piperacillin), cefepime, and ceftazidime.181 Although fluoroquinolones (particularly ciprofloxacin) initially possessed good intrinsic activity against P. aeruginosa, resistance is now common, making empirical fluoroquinolone monotherapy hazardous. Resistance can emerge in Pseudomonas during the course of fluoroquinolone monotherapy.\n\nS. maltophilia is inherently resistant to most standard antibiotics.182 TMP-SMX is the most reliable agent, while fluoroquinolones or ticarcillin-clavulanate have activity against some strains.180 Isolates of S. maltophilia may become resistant in the face of seemingly effective therapy. B. cepacia may be susceptible to acylureidopenicillins, ceftazidime, TMP-SMX, fluoroquinolones, minocycline, and chloramphenicol. Resistance rates are higher in isolates from patients with cystic fibrosis.\n\nAcinetobacter baumannii\n\nEpidemiology."
    }
}